How big is the U.S. veterinary oncology diagnostics market?

The U.S. veterinary oncology diagnostics market size was estimated at USD 992.87 million in 2024 and is expected to reach USD 1.06 billion in 2025.

What is the U.S. veterinary oncology diagnostics market growth?

The global U.S. veterinary oncology diagnostics market is expected to grow at a compound annual growth rate of 8.55% from 2025 to 2030 to reach USD 1.60 billion by 2030.

Which segment accounted for the largest U.S. veterinary oncology diagnostics market share?

Skin cancer held the largest market share in 2024 and is expected to grow at the fastest CAGR of 8.71% during the forecast years. This growth can be attributed to the prevalence of squamous cell carcinoma in cats & dogs, and skin tumors are the most typical form of cancer in older dogs.

Who are the key players in U.S. veterinary oncology diagnostics market?

Some key players operating in the telemedicine market include Zoetis, Antech Diagnostics, Inc. (Mars Inc.), IDEXX Laboratories, Inc., Neogen Corporation, Gold Standard Diagnostics (Eurofins Technologies), Embark Veterinary, Inc., VolitionRx Limited, CANCAN DIAGNOSTICS, Oncotect, and PetDx

What are the factors driving the U.S. veterinary oncology diagnostics market?

Key factors that are driving the market growth include increasing the prevalence of cancer in pets, increasing R&D in early pet cancer diagnosis, and growing focus on animal safety.